Platelets promote growth of ovarian cancer

血小板促进卵巢癌的生长

• 批准号: 10296684
• 负责人: Vahid Afshar-Kharghan
• 金额: $ 47.94万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-08-01 至 2023-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10296684
• 关键词: ADP Receptors; Affect; Agonist; Alpha Granule; Angiogenesis Inhibitors; Anoikis; Antiplatelet Drugs; Area; Aspirin; Behavior; Blood Platelets; Blood Vessels; Cancer Center; Cancer Patient; Cell Adhesion Molecules; Cell Communication; Cell Proliferation; Cells; Chemotactic Factors; Clinical Data; Consequentialism; Data; Diagnosis; Disease; Doctor of Medicine; Epithelial; Event; Extravasation; Fibroblasts; Funding; G-Protein-Coupled Receptors; GTP-Binding Proteins; Growth; In Vitro; Inflammation; Institution; Integrins; Malignant Neoplasms; Malignant neoplasm of ovary; Mediating; Mesenchymal; Molecular; Moon; Mus; Neoplasm Metastasis; Operative Surgical Procedures; Patient Recruitments; Patients; Pericytes; Platelet Activation; Platelet Count measurement; Predictive Value; Primary Neoplasm; Process; Prognosis; Prognostic Marker; Reagent; Recurrence; Reporting; Resected; Resistance; Role; Signal Transduction; Specimen; Stimulus; Stromal Cell-Derived Factor 1; Surface; Survival Rate; Tissue Sample; Tumor Tissue; Tumor-Derived; base; cancer cell; cancer survival; chemotherapy; circulating cancer cell; clinically relevant; density; imaging study; in vivo; migration; mouse model; neutrophil; new therapeutic target; ovarian neoplasm; podoplanin; predictive marker; prognostic value; programs; receptor; response; response biomarker; synergism; thrombocytosis; treatment response; tumor; tumor growth

Project Summary/Abstract Elevated platelet counts are detected in about 30% of ovarian cancer patients and associated with a poor prognosis. We found that thrombocytosis in ovarian cancer is not just epiphenomena of an advanced malignancy, but in fact, platelets promote tumor growth. By reducing platelet counts, we reduced the growth of primary tumors in murine models of ovarian cancer. While most of the previous studies focused on the role of platelets in promoting metastasis, we discovered that platelets increase the growth of primary tumors by enhancing proliferation of cancer cells. The basis for the effect of platelets on tumor growth is the interactions between platelets and cancer cells. We found that ovarian cancer cells activate platelets by secreting ADP, and activated platelets secrete Tgfβ1 that promotes cancer cell proliferation. Blocking or deficiency of P2Y12 ADP receptors on platelets, blocking or deficiency of Tgfβ1 in platelets, or reducing Tgfβ1 receptor 1 (TgfβR1) on cancer cells reduced the pro-growth effects of platelets on ovarian cancer. During studies on ovarian cancer tumors resected from patients and tumor-bearing mice, we observed extravascular platelets inside tumors. We propose that the main effects of platelets on cancer are mediated by extravasated platelets. Migration of platelets outside of blood vessels is not a well-known phenomenon, despite the fact that platelets possess the molecular machinery required for extravasation, and are able to undergo drastic structural changes necessary for extravasation of neutrophils that are professional migratory cells. Our in vivo and in-vitro studies on platelet extravasation into tumors showed that this process is an active process and is reduced by antiplatelet agents (aspirin or ticagrelor). In the first aim of this proposal, we will study the stimuli from tumors that initiate platelet extravasation. We will identify the molecular mechanism of transendothelial migration of platelets, and investigate the facilitatory effects of pericytes on platelets extravasation. After exiting blood vessels, platelets become activated by cancer cells and tumor stroma. In the second aim of this proposal, we will investigate the mechanism of platelet activation in the cancer by dissecting the role of various G-protein-coupled receptors on platelets in tumor growth. We will study the redundancy, synergism, or opposing effects of different platelet G- proteins on platelet-cancer cell interactions. In the third aim, we will investigate the correlation between our findings in the murine models of ovarian cancer and the behavior of ovarian cancer in patients. We have used advanced imaging studies to accurately and objectively quantify platelet density in tumor tissues. We will determine platelet density in tumor specimens resected from 60 patients diagnosed with ovarian cancer in M.D. Anderson Cancer Center (from a pool of 485 patients recruited to the Ovarian Cancer Moon Shots program in our institution). We will correlate platelet density inside tumors with the response rate to surgery, chemotherapy, and antiangiogenic therapy and the survival rates; and determine whether platelet density can be used as a predictive marker for the response rates to therapy and as a prognostic marker for survival and recurrence rates.

项目概要/摘要 约 30% 的卵巢癌患者检测到血小板计数升高，并且与较差的卵巢癌相关 我们发现卵巢癌中的血小板增多不仅仅是晚期的附带现象。 恶性肿瘤，但事实上，血小板促进肿瘤生长，通过减少血小板计数，我们减少了肿瘤的生长。 而先前的大多数研究都集中在卵巢癌小鼠模型中的原发性肿瘤中的作用。 血小板促进转移，我们发现血小板通过以下方式促进原发肿瘤的生长 促进癌细胞增殖的基础是血小板对肿瘤生长的相互作用。 我们发现卵巢癌细胞通过分泌 ADP 来激活血小板，并且 活化的血小板分泌促进癌细胞增殖的 Tgfβ1 阻断或缺乏 P2Y12 ADP。 血小板上的受体，阻断或缺乏血小板中的 Tgfβ1，或减少血小板上的 Tgfβ1 受体 1 (TgfβR1) 在卵巢癌研究中，癌细胞降低了血小板对卵巢癌的促生长作用。 从患者和荷瘤小鼠身上切除肿瘤，我们观察到肿瘤内有血管外血小板。 提出血小板对癌症的主要作用是由血小板外渗的迁移介导的。 尽管血小板具有分子结构，但在血管外并不是众所周知的现象 外渗所需的机械，并且能够经历必要的剧烈结构变化 我们对血小板的体内和体外研究。 外渗到肿瘤中表明该过程是一个活跃的过程，并且可以被抗血小板药物减少 （阿司匹林或替格瑞洛）在本提案的第一个目标中，我们将研究启动血小板的肿瘤刺激。 我们将确定血小板跨内皮迁移的分子机制，以及 研究周细胞对血小板外渗的促进作用。血小板离开血管后。 被癌细胞和肿瘤基质激活 在该提案的第二个目标中，我们将研究 通过剖析各种 G 蛋白偶联受体在癌症中血小板活化的机制 我们将研究不同血小板 G- 的冗余、协同或相反作用。 在第三个目标中，我们将研究我们的蛋白质之间的相关性。 我们使用了卵巢癌小鼠模型的研究结果以及卵巢癌患者的行为。 我们将进行先进的成像研究，以准确、客观地量化肿瘤组织中的血小板密度。 测定从医学博士诊断为卵巢癌的 60 名患者切除的肿瘤标本中的血小板密度。 安德森癌症中心（来自 485 名参加卵巢癌登月计划的患者） 我们的机构）我们将把肿瘤内的血小板密度与手术、化疗的反应率联系起来。 抗血管生成治疗和存活率；并确定血小板密度是否可以用作 治疗反应率的预测标记以及生存率和复发率的预后标记。